Meta-Analysis of Microarray Studies Reveals a Novel Hematopoietic Progenitor Cell Signature and Demonstrates Feasibility of Inter-Platform Data Integration by Sohal, Davendra et al.
Meta-Analysis of Microarray Studies Reveals a Novel
Hematopoietic Progenitor Cell Signature and
Demonstrates Feasibility of Inter-Platform Data
Integration
Davendra Sohal
1, Andrew Yeatts
1, Kenny Ye
1, Andrea Pellagatti
2, Li Zhou
1, Perry Pahanish
1, Yongkai
Mo
1, Tushar Bhagat
1, John Mariadason
1, Jacqueline Boultwood
2, Ari Melnick
1, John Greally
1, Amit
Verma
1*
1Albert Einstein College of Medicine, Bronx, New York, United States of America, 2John Radcliffe Hospital, Oxford, United Kingdom
Abstract
Microarray-based studies of global gene expression (GE) have resulted in a large amount of data that can be mined for
further insights into disease and physiology. Meta-analysis of these data is hampered by technical limitations due to many
different platforms, gene annotations and probes used in different studies. We tested the feasibility of conducting a meta-
analysis of GE studies to determine a transcriptional signature of hematopoietic progenitor and stem cells. Data from
studies that used normal bone marrow-derived hematopoietic progenitors was integrated using both RefSeq and UniGene
identifiers. We observed that in spite of variability introduced by experimental conditions and different microarray
platforms, our meta-analytical approach can distinguish biologically distinct normal tissues by clustering them based on
their cell of origin. When studied in terms of disease states, GE studies of leukemias and myelodysplasia progenitors tend to
cluster with normal progenitors and remain distinct from other normal tissues, further validating the discriminatory power
of this meta-analysis. Furthermore, analysis of 57 normal hematopoietic stem and progenitor cell GE samples was used to
determine a gene expression signature characteristic of these cells. Genes that were most uniformly expressed in
progenitors and at the same time differentially expressed when compared to other normal tissues were found to be
involved in important biological processes such as cell cycle regulation and hematopoiesis. Validation studies using a
different microarray platform demonstrated the enrichment of several genes such as SMARCE, Septin 6 and others not
previously implicated in hematopoiesis. Most interestingly, alpha-integrin, the only common stemness gene discovered in a
recent comparative murine analysis (Science 302(5644):393) was also enriched in our dataset, demonstrating the usefulness
of this analytical approach.
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Introduction
Microarray-based studies of global gene expression have led to
dramatic advances in our understanding of various biological
processes. This technology has become one of the most rapidly
growing investigational methods in medical research and numer-
ous studies have been completed using this method. There are
many available platforms [1] for microarray analysis, and newer
technologies and better gene annotations have led to constant
refinement of these platforms. This has resulted in a large amount
of data in public repositories, like the Gene Expression Omnibus
[2]. Meta-analysis of these data has the potential to yield
important biological information, but is hampered by technical
issues. Cross-platform comparability has been a major hindrance
to this approach. This problem arises because matching probe-sets
across platforms is a difficult task. Different platforms use different
probe lengths and sequences, and mapping them to one common
gene or set of genes is beset with problems. Another limitation is
different gene annotations used by different platforms. The nucleic
acid sequences for various species are submitted to and maintained
in the GenBankH database by the National Center of Biotechnol-
ogy Information (NCBI) [3]. There are different annotation
methods in use to parse these sequences into genes or gene
clusters. UniGene is one method for partitioning GenBank nucleic
acid sequences into unique gene-oriented clusters, each of which
represents a unique gene. These UniGene identifiers (IDs) are
created by finding transcript sequences that match distinct
transcription areas or genes. UniGene IDs have been used as
the matching criterion to merge data across various platforms, but
this has led to a substantial portion of the data remaining
unmatched in previous studies [4,5,6,7,8]. Recent approaches
have tried using Reference Sequence (RefSeq) IDs as the matching
criterion [9]. RefSeq is a public access database, also maintained
by NCBI. This database is built by using sequence data from
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2965GenBank, EMBL Data Library (UK) and DNA Data Bank (Japan)
[10]. This set is also constantly updated, and input from various
investigators is also used to maintain this set. Since both UniGene
and RefSeq are billed as non-redundant sets of transcript IDs, and
have been used in prior studies with mixed results, it is still unclear
as to which approach is better.
We attempted to conduct a meta-analysis of all gene expression
studies using hematopoietic progenitor cells to determine a gene
expression signature characteristic of these cells. Our aim was to
integrate data from all studies that used normal hematopoietic
progenitors and stem cells into a unified normalized database. This
was done using both UniGene as well as RefSeq gene IDs to assess
which identifier provides the best yield. Our results show that
experimental conditions, laboratory where the experiments were
performed and different microarray platforms can result in
significant variability in gene expression patterns from similar
sources of cells. In spite of experimental variability, meta-analytical
studies do have the power to discriminate biologically distinct
tissues on the basis of their normalized gene expression patterns.
Gene expression datasets from similar cells of origin cluster
together despite diseased phenotypes and genetic alterations. The
similarity seen among gene expression profiles of leukemias,
myelodysplasia and normal hematopoietic progenitors, when
compared to non-hematopoietic tissues, validates the functional
discriminatory power of this meta-analysis. Finally, analysis of
merged normal hematopoietic progenitor cell gene expression
datasets led to the discovery of a common gene expression
signature characteristic of these cells. Genes that are most
uniformly expressed in normal hematopoietic tissues and at the
same time being differentially expressed as compared to other
normal tissues were found to be involved in important biological
processes such as hematopoiesis and development. The expression
patterns of these genes were validated in a different microarray
platform using material from three different hematopoietic
progenitor and stem cell experiments.
Methods
Data collection
Normal hematopoietic cell gene expression data were collected
from the NCBI’s Gene Expression Omnibus (GEO) database
(Figure 1). Bone marrow, hematopoietic, CD34 and stem cells
were used as search terms to locate datasets containing gene
expression profiles of normal human hematopoietic cells. Normal
bone marrow/peripheral blood CD34 profiles used as controls in
studies of leukemia and other hematological diseases were also
included. Most studies used the Affymetrix U95, the U133A/B
and the U133 Plus 2.0 Array Platforms. A handful of studies using
older Affymetrix platforms, like the HG-Focus Target Array and
the Full Length HuG Array, were discarded because combining
data from these yielded a lot of non-matching probe-sets.
Gene expression data for other normal tissues assayed on the
same platforms were also obtained from GEO. In a study where
multiple sets were available, we picked one set each for every
tissue, again to minimize correlation within individual datasets.
These were picked using computer-generated random numbers.
To obtain diseased stem cell data, we identified a few studies
with multiple datasets on myelodysplasia, acute myeloid leukemia
(AML) and acute lymphoblastic leukemia (ALL) samples. Where
several datasets were available per study, we picked a subset, again
using random numbers, to obtain about 10 samples per each
study. Table 1 shows the details of these datasets
[11,12,13,14,15,16,17,18,19].
Integration of datasets
Initially, we used the comparison spreadsheets provided by the
chip manufacturer, Affymetrix [20]. These files link the probe-set
IDs of various platforms. However, the yield therein was poor. For
example, using the link file between the U133 and the U133 Plus
platforms, 44635 U133 IDs matched to only 9908 U133 Plus IDs.
Therefore, UniGene and RefSeq IDs were evaluated as variables
Figure 1. Schema of data collection and analysis.
doi:10.1371/journal.pone.0002965.g001
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for each platform were linked to the corresponding UniGene IDs
using annotation files, again provided by Affymetrix [20]. These
UniGene IDs were then used to combine data across the three
platforms. Once probe-set IDs and their expression values were
combined, the expression value for each UniGene ID was
obtained. In many instances, more than one probe-set matched
to the same UniGene ID, resulting in multiple expression values
for each such ID. In such cases, the expression value was
calculated as the mean of the various values for each UniGene ID.
Probe-set IDs which did not match to any UniGene ID were
dropped. Also, if any UniGene ID had data for only one platform,
it was dropped, as it was considered to not match across at least
two of the three platforms. Moreover, in many cases, one probe-set
ID matched to more than one UniGene ID. In such cases, each
UniGene ID was considered to have the same gene expression
value and the data were expanded accordingly.
An identical process was used to merge data across platforms
using RefSeq ID as the match identifier, instead of UniGene ID.
Of interest, RefSeq IDs can be either protein IDs or transcript
IDs. Protein IDs provided slightly better results (as detailed further)
than transcript IDs, and were therefore used in this study.
Data analysis
Once expression values for each UniGene or RefSeq ID were
obtained, these were used to do the analysis. First, the datasets
were normalized using quantile normalization to ensure that
inherent large-scale expression differences in the datasets based on
different sources and laboratories were minimized. Unsupervised
hierarchical clustering using average linkage with (1 - Pearson
correlation coefficient) as the distance measure was done for each
of the three ‘types’ of tissue – normal hematopoietic cells, normal
non-hematopoietic tissues and diseased hematopoietic cells. This
allowed us to look at how the datasets cluster – whether by
platform, laboratory, experiment or otherwise.
To determine a gene signature for hematopoietic progenitor
and stem cells, we used the datasets derived from 57 CD34+ sets,
as whole bone marrow sets may not be a true reflection of these
progenitors, being as they are a mixture of various cell types. To
find out which genes were most consistently expressed across these
samples, we used the coefficient of variation – defined as the
standard deviation divided by the mean – of the expression values
for each ID, calculated across all stem cell samples. The coefficient
of variation was used to incorporate consistency in gene expression
as well as ‘‘enrichment’’ of genes in the hematopoietic progenitor
cells. Prior studies have used similar reasoning [21].
We then used this set of consistently expressed genes and
compared their expression in normal hematopoietic progenitors
versus that in non-hematopoietic tissues, to identify which genes
could differentiate these two tissue sources. This was done using
significance analysis of microarrays (SAM) [22,23]. Similarly,
normal hematopoietic progenitor gene expression was compared
to diseased hematopoietic data, to identify a subset of genes that
may be most relevant to hematological stem cell disorders. All IDs
with missing values for any of the samples were deleted.
All data analyses were done using SAS (SAS Institute, Cary,
NC), the R language and ArrayAssist Expression software package
(Stratagene Corporation, La Jolla, CA).
Results
Integration of data using protein identifiers
A total of 66 individual normal hematopoietic cell expression
profiles were identified in NCBI’s GEO database (Table 1). Nine
were derived from whole bone marrow samples and 57 were from
selected CD34-positive cells. These studies were performed on 3
different microarray platforms (Table 2). Since the probe-set
identifiers and complementary oligos were different on these
platforms, we integrated the data using both UniGene and RefSeq
protein IDs (Figure 1, showing schema).
The Affymetrix annotation files yielded 12,626 unique probe-
sets in the U95 platform, 44,761 in the U133 A/B platform and
54,676 unique probe-sets in the U133 Plus 2.0 platform. Using
UniGene IDs as the matching criterion, 11,635, 40,787 and
45,867 probe-sets matched to at least one other platform,
respectively. After combining data from all the three platforms,
we ended up with a total of 20,717 UniGene IDs. Since one
probe-set can match to more than one UniGene ID and vice versa,
a relatively small number of U95 probe-sets matched to 20,717
UniGene IDs. Using RefSeq protein IDs as the matching
parameter, 11,722, 37,395 and 42,462 probe-sets matched to at
least one other platform, respectively. As many of the probe-sets
Table 1. Sources of data for the meta-analysis*
Author Source of cells No. of datasets Platform
Sternberg A, et al [11] CD34, MDS 22 U133 A/B
Oswald J, et al [12] CD34 3 U133 A/B
Su AI, et al [13] CD34, various normal NHTs 19 U133 A/B
Eckfeldt CE, et al [14] CD34 18 U133 A/B
Bhatia M, et al (GEO) CD34 15 U133 A/B
Pellagatti A, et al [15] CD34, MDS 22 U133 Plus 2.0
Breit S, et al [16] Bone marrow 9 U95
Ge X, et al [17] Various normal NHTs 19 U133 A/B
Gutierrez NC, et al [18] Bone marrow (AML) 9 U133 A/B
Roth RB, et al (GEO) Various normal NHTs 7 U133 Plus 2.0
Cheok MH, et al [19] Bone marrow (ALL) 6 U95
*NHTs: Non-hematopoietic tissues, GEO: Gene Expression Omnibus database set,
MDS: Myelodysplastic syndrome, AML: Acute myeloid leukemia, ALL: Acute lymphoblastic leukemia
Numbers in brackets are reference numbers.
doi:10.1371/journal.pone.0002965.t001
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we ended up with a total of 28,497 unique RefSeq protein IDs that
were common to all three platforms. After removing the probe-sets
where expression values were missing for any dataset, a total of
8,598 unique UniGene IDs and 8,345 unique RefSeq IDs were
obtained that were common to all platforms. These were quantile-
normalized using ArrayAssist (Strategene Corporation, California,
USA) to adjust for hybridization intensities and used for the meta-
analysis.
Experimental conditions, microarray platforms and
source of cells can influence gene expression patterns
Sixty-six hematopoietic gene expression profiles from either
whole bone marrow or selected CD34 cells were grouped using
unsupervised clustering based on Pearson correlation coefficient.
In spite of similar cell types, the studies grouped primarily based
on the laboratory where the data was obtained from. The next
level of clustering was defined by the microarray platform used for
the studies. Barring two bone marrow samples from the Plus 2.0
platform that were similar to one bone marrow sample from the
133A/B platform, all the samples clustered depending on which
platform they were from. The samples from the U95 platform
stayed as a separate group (Figure 2). The last level of similarity
was based on the exact source of the cells used for the RNA.
The correlation coefficients between various datasets validated
the clustering order of laboratory, platform and source (Table 3).
The correlation was strongest between samples obtained from the
same laboratory/study, with a mean (median) absolute correlation
coefficient of 0.87 (0.95). When the platform was the same, a
slightly lesser though still strong correlation of 0.83 was obtained.
These results illustrate that the cause of variability in gene
expression studies can be due to experimental conditions/
protocols used in individual laboratories, platforms used as well
as sources of cells in that order.
Gene expression studies from biologically distinct tissue
types can be compared despite varying platforms and
experimental conditions
We next wanted to determine the degree of dissimilarity of
hematopoietic datasets to gene expression (GE) datasets obtained
from other biologically distinct tissues. GE profiles from human
adrenal, appendix, brain, breast, colon, heart, kidney, liver, lung,
ovary, pancreas, pituitary, prostate, salivary gland, skin, small
intestine, smooth muscle, spleen, stomach, testis, thyroid, urinary
bladder and uterus samples were obtained from the GEO database
and used for this analysis. Unsupervised clustering showed that
samples from the same tissue of origin clustered tightly together in
spite of different platforms/laboratories used for the analysis
Table 2. Platform and tissue type for various datasets.
U95 U133 A/B
U133 Plus
2.0 Total
Normal hematopoietic
stem cells
9 4 61 16 6
Normal tissues,
non-hematopoietic
03 6 7 4 3
Diseased hematopoietic
stem cells
6 2 31 14 0
Total 15 105 29 149
doi:10.1371/journal.pone.0002965.t002
Figure 2. Normal bone marrow HSC clustering. Experimental conditions, microarray platforms and sources of cells influence gene expression
patterns of normal bone marrow derived HSCs. Dendrogram of normal bone marrow derived hematopoietic cells based on unsupervised hierarchical
clustering, using (1 - Pearson correlation coefficient) as the distance measure. Same color in each horizontal row indicates same group.
doi:10.1371/journal.pone.0002965.g002
Table 3. Pairwise absolute correlation coefficients for normal
hematopoietic cell samples
Mean (Range) Median
Same study 0.87 (0.26–1.00) 0.95
Different study 0.35 (0.00–0.93) 0.04
Same platform 0.83 (0.26–1.00) 0.82
Different platform 0.02 (0.00–0.06) 0.01
Same cells (CD34 or BM) 0.58 (0.01–1.00) 0.79
Different cells 0.01 (0.00–0.01) 0.01
doi:10.1371/journal.pone.0002965.t003
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gland, testis, kidney and thyroid tissues from different laboratories
and platforms clearly indicates that our analysis can detect the
similarity of expression at the source tissue level. The mean (and
median) correlation coefficients were also not very dependent on
the laboratory/study or the platform (Table 4). The highest
correlation was observed between similar tissues. These results
demonstrate that despite inter-platform and inter-study variability,
meta-analysis of gene expression profiles has the potential of
revealing differences between tissues with a high degree of
dissimilarity (Table 4).
Gene expression datasets from similar cells of origin can
cluster together despite diseased phenotypes and
genetic alterations
To further test the discriminatory ability of the meta-analysis,
we next grouped datasets from hematologic malignancies with the
normal hematopoietic and non-hematopoietic tissues analyzed
within the same microarray platform (U133 A/B). We wanted to
determine whether biological variability seen in hematopoietic
stem cell disorders such as acute leukemias and myelodysplastic
syndromes would be distinguishable in our analysis. Unsupervised
clustering showed that even though diseased hematopoietic cells
were separated from the normal cells, they were significantly more
dissimilar to non-hematopoietic tissues (Figure 4A). In fact, some
individual GE profiles from bone marrow CD34+ samples from
myelodysplastic syndromes were very similar to normal CD34+
cells and clustered within their groups. We believe that this was a
strong validation of our analytical approach as myelodysplasia is a
preleukemic disorder with varying levels of pathology and can
have cases that are genetically very similar to normal hematopoi-
etic stem cells [24]. We did a similar analysis using RefSeq IDs as
the matching criterion between different datasets. Interestingly,
clustering using RefSeq IDs provided more heterogeneous results
(Figure 4B) and grouped non-hematopoietic tissues along with
hematopoietic tissues, thus demonstrating that UniGene IDs are
better at discriminating biological subsets.
Hematopoietic progenitor and stem cell signature
After validating the strength of the meta-analysis, we wanted to
determine a gene expression signature of hematopoietic progen-
itors. Using the lowest 20
th percentile, to obtain the best possible
initial yield, a total of 1,719 genes were obtained with a low
coefficient of variation among the 57 CD34+ GE profiles (range
0.15–0.39). These were the genes deemed to be most characteristic
of the stem and progenitor cells as their expression was most
consistently enriched among all the samples.
Using this list of genes, we next determined the genes that were
able to discriminate normal hematopoietic and non-hematopoietic
cells by using significance analysis of microarrays (SAM). We used
100 permutations to compute the expected significance ‘score’,
and a false discovery rate (FDR) of 0.29% was achieved by using
the lower- and upper-most 10% of genes. A total of 349 genes
were called as significant (Figure 5).
To better understand how differentially expressed genes were
integrated into specific regulatory and signaling pathway networks,
we used Ingenuity Pathway Analysis (Ingenuity Systems, Redwood
City, USA). Functional analysis of overexpressed genes indicated
that this list is highly enriched for proteins involved in
hematopoiesis and cell cycle, further validating our approach
(Figure 5, Table 5). Several of these genes have already been
described to have important roles in development of the
hematologic system. In addition, our analysis revealed a variety
of novel functional genes like SWI/SNF family member 4,
SMARCE1 and Septin 6. Many of the genes identified in our
database were also found to be enriched in 3 independent HSC
studies performed in our laboratory using a different Nimblegen
platform (Supplementary Table S1). Cross validation suggests that
Figure 3. Distinguishing normal non-hematopoietic tissues. Despite differing platforms and experimental conditions, GE profiles can separate
out normal tissues based on cell/tissue of origin. Dendrogram based on unsupervised hierarchical clustering, using (1 - Pearson correlation
coefficient) as the distance measure. Rectangles indicate samples from the U133 A/B platform and ovals from the U133 Plus 2.0 platform. Triplicate
sets of samples from human liver, heart, testis, kidney, etc. are from different studies, and their grouping together is a strong indicator of
comparability across studies and platforms.
doi:10.1371/journal.pone.0002965.g003
Table 4. Pairwise absolute correlation coefficients for normal
non-hematopoietic cell samples.
Mean (Range) Median
Same study 0.58 (0.27–0.91) 0.59
Different study 0.55 (0.23–0.95) 0.55
Same platform 0.58 (0.24–0.95) 0.59
Different platform 0.51 (0.23–0.88) 0.49
Same tissue 0.77 (0.68–0.95) 0.80
Different tissue 0.57 (0.23–0.88) 0.59
doi:10.1371/journal.pone.0002965.t004
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PLoS ONE | www.plosone.org 5 August 2008 | Volume 3 | Issue 8 | e2965Figure 4. A: Biological relationships identified. Dendrogram of normal hematopoietic, diseased hematopoietic and non hematopoietic tissues
GE profiles reveals biological relationships between them. MDS sets intersperse with normal hematopoietic tissues whereas AML samples are a
separate group, exactly as their biological dissimilarity patterns. Dendrogram based on unsupervised hierarchical clustering, using (1 - Pearson
correlation coefficient) as the distance measure. Same color in each horizontal row indicates same group. UniGene IDs were used for integrating data.
B: Clustering using RefSeq IDs. Same clustering as in 4A, showing poorer performance of RefSeq IDs, compared to UniGene IDs, in uncovering
biological relationships. Dendrogram based on unsupervised hierarchical clustering, using (1 - Pearson correlation coefficient) as the distance
measure. Same color in each horizontal row indicates same group.
doi:10.1371/journal.pone.0002965.g004
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may have functionally important roles in hematopoiesis. We also
found 171 genes to be differentially underexpressed in hemato-
poietic progenitors (Table 6). Our database and integration files
will be online in a searchable format to aid other hematology and
stem cell researchers (http://greallylab.aecom.yu.edu/).
Figure 5. A: ‘‘Stemness genes’’. 349 UniGene IDs were identified as being consistently expressed amongst the normal hematopoietic cells and
differentially expressed between hematopoietic and non-hematopoietic cells. Genes enriched in hematopoietic progenitor and stem cell datasets
were involved in important functional pathways in the cell, including drug metabolism, hematological system development, cell signaling and cancer
and cell death, as shown in the bar graph alongside. One such network is shown, which includes the GATA2, Cyclin E and SMARCE1 genes. B:
Heatmap of ‘‘stemness’’ genes. 349 Unigene IDs were identified as being consistently expressed amongst the normal hematopoietic cells and
differentially expressed between hematopoietic and non-hematopoietic cells. Out of these, 176 genes were enriched in HSC datasets when compared
to other tissue types.
doi:10.1371/journal.pone.0002965.g005
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Microarray analysis of global gene expression has led to rapid
advances in our understanding of various physiological and
pathological processes. Although many hundreds of studies have
been done, doubts have been raised about the reproducibility and
applicability of this data [25,26,27,28]. Inter-study variability can be
attributed to differing probes on the arrays, different protocols for
RNA extraction, labeling and hybridization, and differences in the
quality of cells. In spite of these factors, a number of studies have also
demonstrated reproducibility of microarray studies performed at
different platforms and laboratories, though most used the same
source of RNA for these analyses [29,30,31]. The MicroArray
Quality Control consortium (MAQC) was formed to address these
questionsandrecentlyreportedthatreproducibilitycanbeenhanced
by better matching of microarray probes between platforms [32].
They concluded that matchingprobe-sets within thesameexons and
using similar experimental protocols can lead to more reproducible
results when performed on major commercial microarray platforms.
Our results take these findings a step further and demonstrate that
GE studies done using different platforms and distinct sources of
material have the power to discriminate between biologically distinct
tissues and thus can also be used to analyze various scientific
questions. Earlier attempts to address study specific biases have used
statistical algorithms including ANOVA based correction models
[33,34]. We did not use these algorithms as we found adequate
discrimination between biologically distinct tissues, demonstrating
that the degree of differential gene expression is so large that it is
found even in presence of possible study-specific biases. It is possible
that some of the more subtle results seen in our analysis, however,
may prove artificial once these biases have been removed by
appropriate methods.
Furthermore, this meta-analysis can be accomplished simply by
using UniGene and RefSeq identifiers as common variables
between array platforms, though UniGene is shown to be slightly
better at achieving this discrimination in our dataset. This
difference between UniGene and RefSeq results, albeit small, is
likely due to the different methods of identifying and assigning
transcripts used in the process, and has been observed in prior
studies also [4,5,6,7,8,9,10]. Even though we did observe
variability due to different laboratory protocols as seen by previous
studies, a superior correlation between tissues with similar sources
of cells was able to surpass this limitation and make the meta-
analysis scientifically useful.
Our study demonstrated that results obtained through this
approach can be reconciled with the biology of hematopoietic cells
and malignancies thereof. For example, samples from acute
myeloid leukemia and myelodysplasia were found to be transcrip-
tionally closer to normal hematopoietic cells than non-hemato-
poietic cells, even though these studies are done in many different
laboratories. MDS is a preleukemic disorder of varying grades of
pathology and can have an indolent course in most patients
[15,24]. The fact that MDS samples clustered with normal
hematopoietic samples in some cases shows that our analysis can
interpret biological relationships even between studies performed
by different experimental protocols and laboratories.
After demonstrating that our approach can be used to
biologically characterize sources of cells, we attempted to use this
database to discover gene signatures characteristic of hematopoi-
etic progenitor and stem cells. Due to the heterogeneity of our
source dataset, we imposed very stringent criteria to discover genes
characteristic of hematopoietic progenitors. Out of the 349 genes
that were differentially expressed in normal progenitors, 124 are
differentially expressed in diseased hematopoietic cells, demon-
Table 5. ‘Stemness genes’*
Major functions Well-annotated genes
Gene Expression, Cell Cycle, Cellular Development, ABCC1, CASP8, CSNK1G2, E2F3, GATA2, JARID2, RALBP1, SMARCA4, SMARCE1, STK10, SUMO1, TAL1,
TCF12, TFDP2, USP4, USP7
Cell Morphology, Cellular Assembly and Organization, Cell
Signaling
C1ORF2, GLIPR1, HSPA9, ING2, LPIN1, MAP3K4, MAP4K1, NCK1, NFATC1, PAK2, PPM1F, PPP3CA, TP53,
UBE3A, ZNF84, BRPF1, EWSR1, HSPA4, LYN, MAPKAPK5, PHF21A, PTEN, TIMM17A, TROVE2
Cancer, Cellular Growth and Proliferation,
Tumor Morphology
ATP6V0A2, CD47, HNRPUL1, MLLT10, MPHOSPH9, MTR, PDS5A, SEC63, SH3BGRL
Others TIPRL, TSR1, TXNDC9, SFRS17A, CENTB2, THOC2, KIAA0368, PAX3, TFIP11, TUFT, FMR1, NUFIP1
*Some important genes differentially over-expressed in hematopoietic progenitors, as compared to non-hematopoietic tissues
doi:10.1371/journal.pone.0002965.t005
Table 6. Genes quiescent in HSC progenitor cells*
Major functions Well-annotated genes
Skeletal and Muscular System Development, Function and
Disorders, Genetic Disorders
ADD1, APBB3, ARHGAP1, ATP2A2, BCL2L2, BGN, CALCOCO1, CALD1, CALM1, COL18A1, COL6A1, DDR1,
ESRRA, FMOD, MYH9, NCOA1, PFN2, PXN, RHOC, SQSTM1, TPM1
Cellular Assembly and Organization, Cellular Function and
Maintenance, Cell Signaling
APP, CADM1, CD59, CLSTN1, ERBB2, F8, FLOT1, GDI1, IKBKG, MAPK13, MYO1C, NDRG2, NFE2L1, PTRF,
RAB5B, RAB5C, SFRP1, SHC1, SPTAN1, WFS1
Protein Degradation, Cellular Movement, Cell Morphology ARF3, ARFIP2, CES2, COL1A1, CTNND1, EIF4G1, GSK3A, GSTA1, GSTM2, KIF5C, MFN2, MMP14, PAPSS2,
PCDHGC3, PTPRF, SDC1, TIMP3, TSPAN3
Others CDC42EP4, CHST10, DEFB1, FKBP1A, HDLBP, LPP, S100A13, TEGT, AKAP1, CLOCK, JAM3, PCTK1, TLE2,
TMPRSS6, TNFAIP1, TRIP10, USP13, SPOCK2
*Some important genes differentially under-expressed in hematopoietic progenitors, as compared to non-hematopoietic tissues
doi:10.1371/journal.pone.0002965.t006
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important functional genes. Our search strategy yielded several
genes that were consistently enriched in normal hematopoietic GE
datasets and were found to be involved in cell cycle, growth,
development and hematopoiesis by functional pathway analysis.
Recent studies have supported similar comparative approaches for
more accurate and valid gene target discovery [21,26,35]. Two
recent seminal studies searched for gene signatures of stem cells by
comparing genes enriched in hematopoietic, neural and embry-
onic stem cells and arrived at a total of 283 and 230 common
‘stemness’ genes respectively [21,35]. Even though the experi-
mental techniques and cell types in these two papers were similar,
an initial comparative analysis showed that only 7 ‘stemness’ genes
were common between these two studies. Comparison to a
subsequent third analysis [26] showed even less overlap, with only
one gene being consistently enriched between these three
independent similar studies. Repeat analysis done using different
statistical methods did lead to more gene overlap, but the final
conclusion was that gene array studies of stem cells are influenced
by cell purity and can be contaminated by a high level of non-
specific observations in the data. Consequently, the authors
determined that commonly expressed genes among different
studies may be better representatives of functionally important
stemness genes. Thus, meta-analytical approaches may be a way
to separate functionally important information from experimental
noise. As the genes discovered by our analysis are common in an
extremely variable dataset, they may have a high chance of being
characteristic of human HSCs. Most importantly, alpha-6
integrin, the one gene that was found be enriched in all three
murine stem cell studies, is similar to alpha-4 integrin that was
found to be enriched in our human dataset. Both of these integrins
are known to be expressed on the surface of HSCs and are
implicated in cell migration and homing to the bone marrow. The
functional similarities between these two integrins and the
concurrence of our findings with three landmark stemness gene
studies published in the literature validate our analytical approach.
Our analysis also yielded a set of genes not previously implicated
in hematopoiesis. Some of these genes have interesting functions
and can be potential regulators of HSC function. SMARCE
(SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily e/BAF57) is a key member of the
mammalian SWI/SNF chromatin remodeling complex that is
involved in transcriptional regulation [36]. SMARCE has been
shown to mediate the interaction between the chromatin
remodeling complex and transcription factors and thus could be
partly responsible for the unique chromatin associated with stem
cells [37]. Lyn kinase is a member of the src family of kinases and
has been implicated in granulopoiesis and erythropoiesis and
needs further exploration as a stem cell marker [38,39]. Septin 6 is
a member of a class of proteins involved in cell division, membrane
trafficking and cytoskeletal organization. The roles of septins in
hematopoietic stem cells remain unexplored [40]. Amyloid beta
precursor protein is a cell surface protein with signal-transducing
properties, and it is thought to play a role in the pathogenesis of
Alzheimer’s disease [41]. This protein can activate NEDD8, a
ubiquitin-like protein required for cell cycle progression through
the S/M checkpoint and thus can be potentially involved in cell
cycle control of hematopoietic stem cells. The protein Dp-2 (E2F
dimerization partner 2) belongs to a family of transcription factors
that play an essential role in regulating cell cycle progression [42].
These transcription factors regulate the expression of numerous
critical genes (e.g. cyclin E, CDC2, cyclin A, B-Myb, E2F1, and
p107) involved in cell cycle progression as well as several enzymes
(DNA polymerase a, thymidine kinase, and dihydrofolate
reductase) required for DNA replication [42]. Thus Dp-2 could
certainly be involved in stem cell regulation. In summary, our
analytical approach provides a list of interesting genes for further
scientific and functional validation. Additionally, this dataset can
be used as an online resource for stem cell and hematology
researchers as a control database for comparisons with disease
state GE profiles done in their laboratories.
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